Formulations and Uses of Exendins and Exendin Agonist Analogs

摘要

Provided herein are formulations containing exendins, exendin agonists and/or exendin analogs and methods of using the exendins, exendin agonists and/or exendin analogs and formulations thereof to treat glucagonoma and necrolytic migratory erythema, or to suppress glucagon secretion.

主权项

1. A method for treating glucagonoma or necrolytic migratory erythema in a human in need thereof, the method comprising identifying a human in need of treating glucagonoma or necrolytic migratory erythema; and
administering to the human a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:45, thereby treating the glucagonoma or the necrolytic migratory erythema in the human; wherein SEQ ID NO:45 is:Xaa1 Xaa2 Xaa3 Gly Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Xaa12 Xaa13 Xaa14 Xaa15 Xaa16 Xaa17Ala Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25Xaa26 X1-Z1;wherein
Xaa1 is 4-imidazopropionyl; Xaa2 is Ser, Gly, Ala or Thr; Xaa3 is Ala, Asp or Glu; Xaa5 is Ala or Thr; Xaa6 is Ala, Phe, Tyr or naphthylalanine; Xaa7 is Thr or Ser; Xaa8 is Ala, Ser or Thr; Xaa9 is Ala, Asp or Glu; Xaa10 is Ala, Leu, Ile, Val, pentylglycine or Met; Xaa11 is Ala or Ser; Xaa12 is Ala or Lys; Xaa13 is Ala or Gln; Xaa14 is Ala, Leu, Ile, pentylglycine, Val or Met; Xaa15 is Ala or Glu; Xaa16 is Ala or Glu; Xaa17 is Ala or Glu; Xaa19 is Ala or Val; Xaa20 is Ala or Arg; Xaa21 is Ala, Leu or Lys-NHε—R where R is Lys, Arg, C1-C10 straight chain or branched alkanoyl or cycloalkylalkanoyl; Xaa22 is Phe, Tyr or naphthylalanine; Xaa23 is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa24 is Ala, Glu or Asp; Xaa25 is Ala, Tip, Phe, Tyr or naphthylalanine; Xaa26 is Ala or Leu; X1 is Lys Asn, Asn Lys, Lys-NW—R Asn, Asn Lys-NW—R, Lys-NW—R Ala, Ala Lys-NHε—R, where R is Lys, Arg, C1-C10 straight chain or branched alkanoyl or cycloalkylalkanoyl; Z1 is OH, NH2, Gly-Z2, Gly Gly-Z2, Gly Gly Xaa31-Z2, Gly Gly Xaa31 Ser-Z2, Gly Gly Xaa31 Ser Ser-Z2, Gly Gly Xaa31 Ser Ser Gly-Z2, Gly Gly Xaa31 Ser Ser Gly Ala-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36-Z2, Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37-Z2 or Gly Gly Xaa31 Ser Ser Gly Ala Xaa36 Xaa37 Xaa38-Z2; wherein Xaa31, Xaa36, Xaa37 and Xaa38 are independently selected from the group consisting of Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine and N-alkylalanine; and Z2 is —OH or —NH2; provided that no more than three of Xaa3, Xaa5, Xaa6, Xaa8, Xaa10, Xaa11, Xaa12, Xaa13, Xaa14, Xaa15, Xaa16, Xaa17, Xaa19, Xaa20, Xaa21, Xaa24, Xaa25, and Xaa26 are Ala.